Emerging Therapies for HF Target Different Pathophysiology

Article Figures & Data

Figures

  • Figure 1.

    Change in Cardiac Index (A), Heart Rate (B) and MAP (C) at 16 Weeks

    Reproduced from Bonderman D et al. Riociguat for Patients With Pulmonary Hypertension Caused by Systolic Left Ventricular Dysfunction: A Phase IIb Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Hemodynamic Study. Circulation 2013; 128:502–511. With permission from Lippincott Williams & Wilkins.*On December 1, 2014, this was changed from L.min-1.m-2 to L.min−1.m−2.